RYBREVANT ® (amivantamab-vmjw) plus standard of care approved in the U.S. as first and only targeted regimen to cut risk of disease progression by more than half in second-line EGFR-mutated advanced lung cancer
Approval based on compelling safety and efficacy from the Phase 3 MARIPOSA-2 study, marking the third new indication for RYBREVANT
®
this year, with four indications overall
RARITAN, New Jersey (September 19, 2024)
– Johnson & Johnson (NYSE: JNJ)...
Zur Pressemeldung auf www.jnj.com